Zhang Ting, Shi Wang, Tian Ke, Kong Yushan
Department of Pulmonary and Critical Care Medicine, Affiliated Nanhua Hospital, University of South China, 336 South of Dongfeng Road, Hengyang, 421000, China.
World J Surg Oncol. 2020 Jul 6;18(1):156. doi: 10.1186/s12957-020-01911-x.
This study aimed to investigate the correlation of chaperonin containing t-complex polypeptide 1 subunit 6A (CCT6A) expression with clinicopathological features and survival profiles in non-small cell lung carcinoma (NSCLC) patients.
A total of 381 NSCLC patients with Tumor, Node, Metastasis (TNM) stage I-IIIA who underwent tumor resection were retrospectively screened. Immunohistochemistry staining and semi-quantitative scoring were used to evaluate CCT6A expression in tumor and adjacent tissues. Clinicopathological features were retrieved. Disease-free survival (DFS) and overall survival (OS) were calculated.
CCT6A expression was elevated in tumor tissue (CCT6A high 47.5% vs. low 52.5%) compared with adjacent tissue (CCT6A high 30.4% vs. low 69.6%) (P < 0.001), and ROC curve displayed that CCT6A could distinguish tumor tissue from adjacent tissue. Moreover, tumor CCT6A high expression was associated with lymph node metastasis (P = 0.001), elevated TNM stage (P = 0.002), and abnormal carcinoembryonic antigen (P = 0.022). Kaplan-Meier curves displayed that tumor CCT6A high expression was negatively correlated with DFS and OS (all P < 0.001). Cox's regression analysis disclosed that tumor CCT6A high expression independently predicted worse DFS (P < 0.001) (hazard ratio (HR) 1.659 (95% confidence interval (CI) 1.318-2.089)), and OS (P < 0.001) (HR 1.779 (95%CI 1.378-2.298)).
CCT6A may present some clinical value in the management of NSCLC.
本研究旨在探讨含t-复合体多肽1亚基6A（CCT6A）的伴侣蛋白表达与非小细胞肺癌（NSCLC）患者临床病理特征及生存情况的相关性。
回顾性筛选381例接受肿瘤切除的肿瘤、淋巴结、转移（TNM）分期为I-IIIA期的NSCLC患者。采用免疫组织化学染色和半定量评分法评估肿瘤组织和癌旁组织中CCT6A的表达。收集临床病理特征。计算无病生存期（DFS）和总生存期（OS）。
与癌旁组织（CCT6A高表达30.4%，低表达69.6%）相比，肿瘤组织中CCT6A表达升高（CCT6A高表达47.5%，低表达52.5%）（P < 0.001），ROC曲线显示CCT6A可区分肿瘤组织和癌旁组织。此外，肿瘤CCT6A高表达与淋巴结转移（P = 0.001）、TNM分期升高（P = 0.002）及癌胚抗原异常（P = 0.022）相关。Kaplan-Meier曲线显示，肿瘤CCT6A高表达与DFS和OS呈负相关（均P < 0.001）。Cox回归分析显示，肿瘤CCT6A高表达独立预测DFS更差（P < 0.001）（风险比（HR）1.659（95%置信区间（CI）1.318 - 2.089））和OS更差（P < 0.001）（HR 1.779（95%CI 1.378 - 2.298））。
CCT6A在NSCLC的管理中可能具有一定的临床价值。
